Natera Inc.

NASDAQ: NTRA · Real-Time Price · USD
152.20
1.27 (0.84%)
At close: May 01, 2025, 12:00 PM
0.84%
Bid 151.48
Market Cap 20.63B
Revenue (ttm) 1.7B
Net Income (ttm) -190.43M
EPS (ttm) -1.53
PE Ratio (ttm) -99.48
Forward PE -219.04
Analyst Buy
Ask 152.79
Volume 323,610
Avg. Volume (20D) 1,689,203
Open 151.90
Previous Close 150.93
Day's Range 147.75 - 153.70
52-Week Range 92.14 - 183.00
Beta 1.80

About NTRA

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; a...

Sector Healthcare
IPO Date Jul 1, 2015
Employees 4,424
Stock Exchange NASDAQ
Ticker Symbol NTRA
Full Company Profile

Analyst Forecast

According to 17 analyst ratings, the average rating for NTRA stock is "Buy." The 12-month stock price forecast is $185, which is an increase of 21.55% from the latest price.

Stock Forecasts

Next Earnings Release

Natera Inc. is scheduled to release its earnings on May 8, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Just now
-2.56%
NTRA stock has given up its prior loss. Natera sha... Unlock content with Pro Subscription
22 hours ago
-2.56%
Natera shares are trading lower. The company reported results from its DEFINE-HT clinical trial.